Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7279241 | 0.81 | — | — | |
| SCHEMBL1708138 | 0.79 | — | — | |
| SCHEMBL27742869 | 0.79 | — | — | |
| SCHEMBL27601379 | 0.79 | — | — | |
| SCHEMBL28976446 | 0.77 | ALDH1A1 (0.33) | TSHRALDH1A1MAPTPTGS1TP53 | |
| SCHEMBL21295105 | 0.75 | ALDH1A1 (0.36) | TSHRALDH1A1MAPTPTGS1TP53 | |
| SCHEMBL27477795 | 0.73 | ALDH1A1 (0.35) | TSHRALDH1A1MAPTPTGS1 | |
| SCHEMBL27783691 | 0.73 | MAPT (0.35) | TSHRALDH1A1MAPTPTGS1 | |
| SCHEMBL27928016 | 0.73 | ALDH1A1 (0.31) | TSHRALDH1A1MAPTPTGS1 | |
| SCHEMBL4821291 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1501507-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1501507-A4 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060030582-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | DEMARTINO JULIE | 2006-02-09 | — | — | US | disclosed |
| US-20050107422-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME LLC | 2005-05-19 | — | — | US | disclosed |
| US-20050101628-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME LLC | 2005-05-12 | — | — | US | disclosed |
| EP-1501507-A2 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6812234-B2 | CCR-2; INFLAMMATORY, IMMUNOREGULATORY, ALLERGIC, AND AUTOIMMUNE DISORDERS AND DISEASES | MERCK & CO., INC. | 2004-11-02 | — | — | US | disclosed |
| US-20040167156-A1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK SHARP & DOHME LLC | 2004-08-26 | — | — | US | disclosed |
| WO-2003092586-A2 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030582-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR2, CCR5 | TSHR 277/4885ALDH1A1 2012/4885MAPT 3858/4885 |
| US-20050107422-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR9, CCR2 | TSHR 293/4885ALDH1A1 2141/4885MAPT 3972/4885 |
| US-20050101628-A1 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | CCR2, CCR9, CCR1 | TSHR 317/4885ALDH1A1 2240/4885MAPT 4485/4885 |
| US-20040167156-A1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCRL2, CCR5 | TSHR 447/4885ALDH1A1 1905/4885MAPT 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.